Anti-TNF alpha therapy in inflammatory lung diseases

作者：Malaviya Rama; Laskin Jeffrey D; Laskin Debra L^*

来源：Pharmacology & Therapeutics, 2017, 180: 90-98.

DOI：10.1016/j.pharmthera.2017.06.008

• TNF
• Pulmonary disease
• Lung injury
• Biologics
• Inflammation

Increased levels of tumor necrosis factor (TNF) alpha have been linked to a number of pulmonary inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), sarcoidosis, and interstitial pulmonary fibrosis (IPF). TNF alpha plays multiple roles in disease pathology by inducing an accumulation of inflammatory cells, stimulating the generation of inflammatory mediators, and causing oxidative and nitrosative stress, airway hyperresponsiveness and tissue remodeling. TNF alpha-targeting biologics, therefore, present a potentially highly efficacious treatment option. This review summarizes current knowledge on the role of TNFa in pulmonary disease pathologies, with a focus on the therapeutic potential of TNF alpha-targeting agents in treating inflammatory lung diseases.

• 出版日期2017-12
• 单位rutgers